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ABSTRACT  
Objective: The LupusQoL is a reliable and valid health-related quality of life (HRQoL) 
measure for adults with systemic lupus erythematosus (SLE).  This study evaluates the 
responsiveness and minimal important differences (MID) for the eight LupusQoL domains.     
Methods: Patients experiencing a flare were recruited from nine UK centres. At each of the 
ten monthly visits, HRQoL (LupusQoL, SF-36), global rating of change (GRC) and disease 
activity (DA) using the BILAG-2004 index were assessed.  The responsiveness of the 
LupusQoL and the SF-36 was evaluated primarily when patients reported an improvement or 
deterioration on the GRC scale and, secondly, with changes in physician-reported DA. MIDs 
were estimated as mean changes when minimal change was reported on the GRC scale. 
Results: 101 patients were recruited. For all LupusQoL domains, mean HRQoL worsened 
when patients reported deterioration and improved when patients reported an 
improvement in GRC; SF-36 domains showed comparable responsiveness. Improvement in 
some domains of the LupusQoL/SF-36 was observed with a decrease in DA but when DA 
worsened, there was no significant change. LupusQoL MID estimates for deterioration 
ranged from -2.4 to -8.7 and for improvement, 3.5 to 7.3; for the SF-36, -2.0 to -11.1, and 2.8 
to 10.9 respectively. 
Conclusion: All LupusQoL domains are sensitive to change with patient-reported 
deterioration or improvement in health status. For DA, some LupusQoL domains showed 
responsiveness when there was improvement but none for deterioration. LupusQoL items 
were derived from SLE patients and provide the advantage of disease-specific domains, 
important to them, not captured by the SF-36. 
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SIGNIFICANCE AND INNOVATIONS 
• The LupusQoL, a patient-derived disease-specific HRQoL measure for adults is 
sensitive to change in health status and can be recommended for use in clinical trials 
• The LupusQoL domain MIDs for deterioration range from -2.4 to -8.7 and for 
improvement, 3.5 to 7.3 
• LupusQoL items were derived from SLE patients and provide the advantage of 
disease-specific domains, important to them, not captured by the SF-36 
• These results will allow appropriate power calculations and interpretation of HRQoL 
measurements in clinical trials and longitudinal observational studies. 
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The survival of patients with SLE has improved in the last 50 years from less than 50% at 5 
years in 1955 to 85% at 10 years and recently, 75% at 20 years (1). The Outcome Measures 
in Rheumatology Clinical Trials (OMERACT) group and the US Food and Drug Administration 
(FDA) have recommended that for clinical trials and observational studies, health-related 
quality of life (HRQoL) should be assessed using both generic and disease-specific measures, 
allowing comparison with healthy samples, estimates of health utilities and disease-specific 
information known to be important to patients (2,3). HRQoL instruments provide a 
standardized, valid, and reliable way of gaining the patient’s perspective as to “how they 
are” and the benefits and limitations of interventions. HRQoL in SLE is poorly correlated with 
the clinicians’ assessment of disease activity and damage (4,5) as some symptoms are only 
known to the patient (e.g. fatigue, nausea). Therefore, HRQoL measurement can provide 
‘added value’ because it can supply information not captured by other outcome measures. 
Thus, HRQoL may be informative not only as an efficacy measure, but also potentially 
reflects safety issues and for these reasons HRQoL is becoming important in labelling claims 
(6,7).  
 
The LupusQoL is a valid, reliable patient-derived, disease-specific HRQoL measure for adults 
with SLE (8) that contains items/domains more relevant to patients with SLE than generic 
measures (9). As with many HRQoL measures, the interpretation of the data may be 
problematic and should not be based solely on p values, especially if HRQoL is a secondary 
outcome when a trial tends not to be powered for HRQoL. To aid the interpretation of the 
LupusQoL, evaluation is required to (a) assess its sensitivity to change (the ability to detect 
an improvement or deterioration when patients deem themselves to have improved or 
deteriorated) (10) as advocated by the regulatory bodies (2) and (b) to estimate the minimal 
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important difference (MID) (the smallest difference that patients perceive as beneficial or 
harmful) (11).  
 
This study aimed to evaluate these parameters, using both anchor-based and distribution-
based methods, for each domain of the LupusQoL and the SF-36: specifically, the scale’s 
ability to (a) detect an improvement in HRQoL following treatment of a severe or moderate 
flare, (b) detect deterioration in HRQoL e.g. when patients fail to have their disease 
controlled by their initial treatment plan and (c) to estimate the MIDs. The responsiveness of 
the LupusQoL and the SF-36 was evaluated primarily when patients reported an 
improvement or deterioration on the global rating of change (GRC) scale (12) and, secondly, 
with changes in physician-reported disease activity (DA). 
 
PATIENTS AND METHODS 
Study design   
This was a prospective, longitudinal, observational study. The study was granted multi-
centre Research Ethics Committee approval (MREC 02/05/035) and was carried out in 
compliance with the Helsinki Declaration, at the following rheumatology units: Bangor, 
Birmingham (two centres), Blackburn, University College London, Nottingham, Manchester, 
Doncaster and Sheffield.  All patients gave written informed consent.  
 
Patients  
 
Patients were recruited over an 18-month period and were followed at four-weekly (± 2 
weeks) intervals for nine months. The inclusion criteria were: fulfilment of ≥ four ACR criteria 
for SLE (13,14), ≥ 16 years old, literate in the English language, willing to give written 
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informed consent and a flare of SLE requiring specific treatment. Flare was defined as a 
significant increase in disease activity resulting in a BILAG-2004 index A or B score based on 
criteria that are new or worse (15,16,17). To be included in this study, patients had to 
require an increase in therapy defined as one or more of the following:  an increase of oral 
prednisolone to ≥ 20 mg/day, introduction of methotrexate, parenteral methylprednisolone, 
and/or other immunosuppressive therapy (e.g. cyclophosphamide, rituximab). The exclusion 
criteria were:  < 16 years old, inability to read English, inability to give valid consent and 
pregnancy.  
 
Measures 
 
Demographic and clinical measures 
 
Demographic and clinical details were recorded at baseline by the clinician (date of birth, 
gender, date of diagnosis, fulfilment of ACR criteria for SLE, ethnic group (18), marital status 
and current therapy). The Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology Damage Index (SDI) (19) was reported twice: at baseline and at the 
end of the study. The BILAG-2004 disease activity index was assessed at each visit.  
 
LupusQoL 
The original English version of the LupusQoL (4 week recall period) (8) was completed by the 
participant at each time-point.  It has eight domains: physical health, pain, planning, body 
image, burden to others, intimate relationships, emotional health and fatigue.  This 
instrument has good internal reliability (Cronbach’s α 0.88 to 0.96), test-retest reliability (ICC 
0.72 to 0.93) and concurrent validity with comparable domains of the SF-36 (ICC 0.71 to 
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0.79).  It has acceptable ceiling effects and minimal floor effects. Scoring of the LupusQoL is 
such that 0 represents worst health and 100 best health for each domain (8).    
SF-36 
Patients completed the SF-36 (UK version 1) with a four-week recall at each assessment (20). 
The SF-36 measures eight dimensions of health: physical functioning, social functioning, role 
limitations due to physical problems, role limitations due to emotional problems, mental 
health, energy/vitality, bodily pain, and general health perception. Domain scores can range 
from 0 to 100 (higher scores indicate a better HRQoL).  
 
Global Rating of Change (GRC) Scale 
To estimate patient-reported change, each domain of the LupusQoL and the SF-36 
incorporated the global rating of change scale (12). Patients were asked to rate change in 
each domain over the past four weeks from +7 (a very great deal better) to -7 (a very great 
deal worse) with 0 indicating no change. Scores of -1 to +1 were classified as ‘no change’, 
with -7 to -2 as ‘deterioration’ and 2 to 7 as ‘improvement’.  Within the deterioration and 
improvement categories, scores of +2, +3 and -2, -3 were considered to represent minimal, 
but nevertheless,  important changes.  
 
BILAG-2004 index 
At baseline and each review visit, the clinician assessed the SLE disease activity using the 
BILAG-2004 index (15). The BILAG-2004 category scores “A” to “E” are based on intention to 
treat: “A” denotes severe disease activity, “B” moderate disease activity, “C” mild stable 
disease, “D” inactive disease but previously affected system and “E” a system that has never 
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been involved.  Changes in overall disease activity between consecutive time-points, as 
measured by the BILAG-2004 index, were defined as follows:  
• Deterioration (any system to A from B/C/D or to B from C/D) (21)  
• Improvement (all systems A to B/C/D and B scores to C/D) (22) with no deterioration 
in any system (one persistent B score is allowed if there is improvement from A or B 
in at least one other system) 
• Persistent inactive disease (all systems C/D/E at both time-points) 
• Persistent active disease (A or B systems remained unchanged but without overall 
improvement or deterioration).  
When changes of activity of a single BILAG system were analysed, the above definitions 
apply but only for that system (no persistent B score is allowable for improvement). 
 
Statistical Methods   
The sample size calculation was based on summary statistics from previous work during the 
LupusQoL development and on the changes of the physical health domain. A sample size of 
52 would have 80% power to detect a difference in means of 4 assuming a standard 
deviation of 10, using a paired t test with a 5% significance level. The intention was to recruit 
104 patients: a) to allow for patients who did not report changes in HRQoL; b) because we 
expected the effect size for the other domains to be smaller; c) to allow for missing data; and 
d) to allow for dropouts. All analyses were performed using Stata Release 13 (Stata Corp, 
Texas USA) (23). 
 
Determination of sensitivity to change (responsiveness) 
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The primary method for assessing responsiveness was based on patient-reported GRC 
scores. Responsiveness was also examined using physician-reported disease activity change 
scores.  Based on GRC or disease activity change scores, each domain of both HRQoL 
measures was evaluated to determine its ability to: (a) detect an improvement in HRQoL 
following treatment of a flare and (b) detect deterioration in HRQoL e.g. when treatment has 
undesirable and troublesome side effects or the patients fail to have their disease controlled 
by their initial treatment plan. Responsiveness was estimated as the mean change in HRQoL 
domain score across (a) participant-reported improvements or improvement of disease 
activity, and (b) participant-reported deteriorations or deterioration of disease activity, 
between consecutive assessments. 95% confidence intervals were presented, using robust 
methods for estimating the standard error in Stata, based on the approach proposed by 
Huber (24).  
 
Additionally, standardised response means (SRM), the ratio of the mean change of the 
domain score between consecutive observations and the corresponding estimated standard 
deviation (SD) of the change score, were reported based on GRC scores.  Effect sizes (ES), for 
which the mean change of each domain score was standardised using the estimated SD of 
the baseline score, were also reported based on GRC scores.  Both are standardised 
measures of responsiveness, with SRM having the advantage that it is less affected by the 
heterogeneity of the sample by using a more appropriate SD, namely that of the change 
score.   SRMs or ESs of 0.2, 0.5 and 0.8 are deemed to demonstrate small, moderate or large 
responsiveness respectively (25).  
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We also explored changes in relevant domains of the LupusQoL and SF-36 to changes of key 
systems in the BILAG-2004 index.  The musculoskeletal and mucocutaneous systems are the 
most commonly affected systems in SLE patients, therefore we explored the relationships 
between (i) musculoskeletal system changes and the changes in physical health and pain 
domains of the LupusQoL and the changes in physical functioning and bodily pain domains of 
the SF-36 and (ii) the mucocutaneous system changes and the changes in the body image 
domain of the LupusQoL.   
 
Estimation of the Minimum Important Difference/s (MIDs) 
Methods for estimating the Minimal Important Difference (MID) are either anchor-based 
(sometimes referred to as minimal clinical important difference (MCID)) or distribution-
based (often referred to as MID). We use the term MID as this is the more dominant term in 
the current literature (26) for both approaches as ultimately they seek to establish the same 
property.  We will illustrate the difference in the methodology used by using MID(a) for the 
anchor-based approach or MID(d) for the distribution-based approach. No single approach is 
perfect and multiple strategies are likely to enhance the interpretability of changes in HRQoL 
scales (11,27). An anchor-based method was used as the primary approach (as preferred by 
the FDA) (2), based on the average change in LupusQoL or SF-36 scores for the subset of 
patients who were considered to have experienced a small but discernible change in that 
particular HRQoL domain. These analyses were complemented by distribution-based 
approaches based around the common standards of 1 standard error of the mean (SEM), 
using data from McElhone et al (8) and 0.5 SD, which corresponds to a ‘medium effect’ 
(28,29). 
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RESULTS 
Patient recruitment and follow-up 
During the eighteen-month recruitment period, a total of 115 patients from nine centres 
were deemed eligible for the study and approached.  Four patients declined to participate 
and 111 patients were recruited. Of these, 101 patients completed the study and are 
reported here (Figure 1).    
Patient demographics, disease activity and damage 
The baseline demographic, clinical characteristics and HRQoL of the patients are provided in 
Tables 1 and 2. There were 42 ‘A’ flares in 41 patients (one patient had A flares in both 
musculoskeletal and mucocutaneous systems) and 130 ‘B’ flares, with some patients having 
both ‘A’ and ‘B’ flares. The frequency of flares in the different BILAG-2004 systems is shown 
in supplementary table 1. Only 28% of the patients scored ≥ 1 for damage on the SDI (Table 
2). 
 
HRQoL: LupusQoL and SF-36 at baseline (flare) 
HRQoL was severely impaired at baseline with mean LupusQoL scores ranging from 33.3 
(Burden to others) to 51.4 (Emotional Health), whilst mean SF-36 domain scores ranged from 
12.1 (Role Physical) to 51.0 (Mental Health) (Table 2). Scores for comparable LupusQoL/SF-
36 domains were highly correlated (Pain/Bodily Pain: r=0.76; Physical Health/Physical 
Function: r=0.82; Emotional Health/Mental Health: r=0.74; Fatigue/Vitality: r=0.66) although 
observed mean scores were consistently higher for LupusQoL than SF-36 domains (Table 2).   
 
Sensitivity to change (Responsiveness)  
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There were 911 (90.2%) completed HRQoL questionnaires across the 10 time-points.  The 
amount of complete change score data, however, varied across HRQoL domains and time-
points. For the LupusQoL six of the eight domains had over 83% of change score data 
available, ranging from 776 (85.4%) for physical health to 757 (83.3%) for fatigue, with the 
other domains having lower percentages of change score data available (body image 616 
[67.8%] and intimate relationships 541 [59.5%].  For the SF-36 the amount of change score 
data available ranged from 773 (85.0%) for general health to 761 (83.7%) for role physical. 
All domains of the LupusQoL worsened significantly when patients reported a deterioration 
of their health status and all domains improved significantly when patients reported an 
improvement in their health status (Tables 3 and 4). There was little change in the mean 
LupusQoL scores when patients reported no change in their health status (+1, 0, -1 on the 
GRC score).  Mean change scores ranged from 0.6 (95% CI -0.4 to 1.6) in the physical health 
domain to 2.5 (95% CI 1.2 to 3.8) in the burden to others domain.  For deterioration, the 
mean LupusQoL change scores ranged from -2.5 (95% CI -4.2 to -0.8) for the body image 
domain to -7.7 (95% CI -14.7 to -0.6) for the intimate relationship domain. For improvement, 
the mean LupusQoL change scores ranged from 5.6 (95% CI 4.2 to 7.1) in the Physical Health 
domain to 10.4 (95%CI 7.7 to 13.1) in the burden to others domain. The results for the SF-36 
were similar (Tables 3 and 4).  
 
When the overall disease activity lessened, six domains of the LupusQoL (physical health, 
pain, planning, emotional health, body image and fatigue) and seven of the SF-36 domains 
(physical functioning, bodily pain, mental health, social functioning, role emotional, role 
physical and vitality) showed an improvement; for the remaining  LupusQoL and SF-36 
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domains, changes were small and non-significant.  When overall disease activity increased 
there was no significant decrease in any of the scores of the LupusQoL or SF-36 domains 
(Supplementary Tables 2 and 3).  An improvement in the disease activity of the 
musculoskeletal system was associated with significant improvements in both the LupusQoL 
and SF-36 physical function and pain domains.  When the disease activity worsened only a 
significant deterioration of the LupusQoL pain domain was observed, although numbers of 
patients were low.  When disease activity altered on the mucocutaneous system no 
significant change was observed in the LupusQoL body image domain (Supplementary Table 
4). 
 
For deterioration in GRC, LupusQoL domain SRMs ranged from -0.16 (Body Image) to -0.35 
(Pain) and those for SF-36 ranged from -0.22 (General Health) to -0.38 (Bodily Pain); for 
comparable domains, LupusQoL SRMs were similar in size to SF-36 SRMs (Supplementary 
Table 5).   For improvement, LupusQoL domain SRMs ranged from 0.36 (Planning and 
Intimate Relationships) to 0.55 (Burden to Others) and those for SF-36 ranged from 0.25 
(Role Emotional) to 0.61 (Bodily Pain); for comparable domains, LupusQoL and SF-36 SRMs 
were similar in size (Supplementary Table 5).  For ESs, patterns of sensitivity to change 
measures were similar (Supplementary Table 6). 
 
Minimal Important Differences (MID) 
Using the anchor–based approach, the MIDs(a) for improvement and for deterioration for 
each of the LupusQoL and SF-36 domains are given in Table 5. For deterioration, the mean 
MID(a) for the LupusQoL ranged from -2.4 (95% CI -4.8 to 0.1) for body image to -8.7 (95% CI 
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-18.9 to 1.6) for intimate relationships, and for improvement from 3.5 (95% CI 0.5 to 6.5) for 
body image to 7.3 (95% CI 4.0 to 10.6) for burden to others. For the SF-36, for deterioration, 
the mean MID(a) ranged from -2.0 (95% CI -3.4 to -0.5) for general health to -11.1 (95% CI -
17.8 to -4.5) for role physical and for improvement, the mean MID(a) ranged from 2.8 (95% 
CI 1.2 to 4.5) for general health to 10.9 (95% CI 8.0 to 13.8) for bodily pain and 10.9 (95% CI 
7.5 to 14.3) for vitality. For comparable domains, for both deterioration and improvement, 
mean MIDs(a) for LupusQoL tended to be smaller in size than mean SF-36 MIDs(a) (Table 5).  
Compared to anchor-based approaches, using distribution-based approaches based on 0.5 
SD, LupusQoL domain MIDs(d) were larger still, but more consistent between domains, 
ranging from 12.9 (Emotional Health) to 16.7 (Intimate Relationships).  For SF-36 domains, 
MIDs(d) based on 0.5 SD were also larger, albeit relatively less so, ranging from 9.3 (General 
Health Perceptions) to 19.7 (Role Emotional).   Estimates of MID(d) using 1 SEM were larger 
than anchor-based estimates, ranging from 6.6 for Emotional Health to 13.2 for Burden to 
Others (Supplementary Table 7). 
 
DISCUSSION 
Knowing whether, or to what extent, a patient has improved or deteriorated following a 
course of treatment is fundamental to clinical practice. This work has demonstrated that all 
eight of the LupusQoL domains are sensitive to change and able to identify patient-reported 
improvements and deteriorations. With changes in physician-reported disease activity, there 
were less consistent findings: improvement in six of eight LupusQoL domains when disease 
activity lessened but little or no responsiveness with worsening disease activity.  There may 
be several reasons for this: (a) physician-reported disease activity measures a different 
Page 16 of 38
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
Sensitivity to change (Responsiveness) and Minimal Important Difference (MIDs) of the LupusQoL   
16 
 
concept to HRQoL, hence the FDA recommendation that responsiveness should be 
measured against the patient GRC, (b) patients may perceive improvement more clearly 
than deterioration, particularly having presented with flare, (c) the number of patients in the 
deterioration sub-groups, especially when single BILAG system changes were examined, may 
be insufficient to detect significant changes and (d) the assessment over a month may be too 
short a time period for change to occur in some domains of the LupusQoL following a change 
in disease activity.  
Different LupusQoL domains had different patient-reported MIDs(a) which also differed for 
deterioration and improvement.  When looking for an improvement in SLE, the MID ranges 
from 4 to 7 points depending on the domain. For the SF-36 the MIDs range from 3 to 11 
points.  These results will allow appropriate power calculations and interpretation of HRQoL 
measurements in clinical trials and longitudinal observational studies. MIDs are not without 
problems in that different methodologies (anchor-based or distribution-based) generated 
somewhat different MIDs and the MID reflects the difference that is important at a group, 
but not the individual, level.  Regulatory bodies advocate the use of anchor-based methods 
in the estimation of responsiveness as they use patient ratings (2), even though the 
reliability of patients' estimates of their previous health status has been questioned (30,31). 
 
This study recruited patients with moderate or severe flares and is likely to be representative 
of patients recruited into clinical trials. It is noteworthy that the original LupusQoL mean 
scores derived from consecutive outpatients at UK centres were strikingly higher (by 
approximately 20 to 35 points) across all domains (8) than the baseline values for these 
patients with moderate or severe flares. Such large differences suggests that a flare of SLE 
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has a very significant impact on all aspects of HRQoL and may also explain why the LupusQoL 
is less responsive to deterioration of disease activity as patients already have poor health.   
 
There have been two publications regarding the sensitivity to change of the LupusQoL. Using 
the Canadian version of the LupusQoL, Touma et al (32) concluded that its responsiveness 
was similar to that of SF-36 following a 12 month prospective cohort study of consecutive 
patients at a single tertiary centre. However, only changes in the disease activity measure, 
the SLEDAI-2000 (33,34) were used to estimate responsiveness whilst in our study the 
patient-reported GRC scale was used to estimate responsiveness as recommended by the 
regulatory bodies (2,3) in addition to a disease activity measure (the BILAG-2004 index). 
Results of a multi-tertiary centre cohort study, recruiting consecutive patients using the 
French version of the LupusQoL, assessed patients at 3 and 6 months (35).  The anchors for 
improvement and deterioration included a patient-reported 7-point Likert scale and VAS 
(100mm).  A Likert scale of five patient-reported symptoms extracted from the Systemic 
Lupus Assessment Questionnaire (SLAQ) was also used (36,37).  The LupusQoL-FR and the 
SF-36 showed comparable responsiveness and the MIDs were similar for both measures. 
Despite the different patient selection criteria (consecutive recruitment/SLE flare; single 
tertiary centre/multi-centre study), length of follow-up period, and different methods 
(anchor-based, distribution-based) and scales to evaluate sensitivity to change (GRC scale, 
SLAQ, SLEDAI-2000), there is agreement that the LupusQoL demonstrates sensitivity to 
change in SLE.  
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In this study that recruited patients with active lupus, the LupusQoL and SF-36 appear to be 
more responsive to improvement than deterioration; this was also noted in the French study 
(35).  It has been reported previously that patients with other conditions detected 
improvements following treatment more easily than deterioration. Patients reported that 
they often did not realize how much they had deteriorated until they started to improve 
(38). This is an encouraging finding especially when the LupusQoL is recommended for use in 
clinical trials. When patients improve during and after an intervention, the LupusQoL should 
be able to detect these changes.  In contrast, in a study of SLE patients that employed the 
SF-36, deterioration of HRQoL was perceived more readily than improvement (39). However, 
this paper described studies in a clinical trial setting, using an immunological anchor as a 
marker of improvement.    
    
In spite of a large data set and rigorous follow-up schedule our study had little missing 
change score data on most domains (approximately 15%).  The majority of patients were 
Caucasians (62.6%), but other groups were represented including 15.2% of South Asian 
origin. Although monthly follow-ups may not have allowed sufficient time for an 
intervention to take effect and for some HRQoL domains to change as different domains 
may change over different periods of time, monthly reviews did ensure that relapses and the 
effects of these on HRQoL were not missed.   
 
The assessment of lupus disease in clinical trials should involve patient-reported outcomes 
including a global assessment and specific instruments that capture the impact of the 
disease on the patient quality of life.  The LupusQol has previously demonstrated good 
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construct, face, discriminative and concurrent validity, and internal and test-retest reliability, 
and has been mapped to the SF-6D (8,40,41). Linguistic validations have enabled the 
instrument to be employed successfully in 51 countries using 77 different languages 
[http://www.lupusqol.com]. This study demonstrates the responsiveness of the instrument, 
further construct validity as compared with the SF-36 and provides the MIDs. The SF-36 and 
the LupusQoL are similar in terms of responsiveness, but the items on the LupusQoL were 
informed by patients with SLE and therefore, it has the advantage of several SLE specific 
domains that are important to patients (planning, burden to others, intimate relationships, 
body image) (9) that are not captured by the SF-36.  
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Table 1: Patient Baseline Demographic and Clinical Characteristics, n (%) unless stated  
 
Females  95 (94%) 
Mean (SD) age/disease duration (years)  40.9 (12.8)/9.3 (8.1) 
Ethnic distribution 
(n=99) 
  
 
White (British, Irish) 
Black (Caribbean, African) 
Asian (Indian, Pakistani, Bangladeshi) 
Chinese  
Other Asian 
Mixed 
62 (63%)  
12 (12%)  
14 (14%)  
1 (1%) 
3 (3%) 
7 (7%) 
Clinical 
characteristics 
(ACR criteria) 
  
  
Malar rash  
Photosensitivity rash 
Discoid rash  
Mouth ulcers  
Arthritis 
Serositis 
Renal disease  
Central nervous system disease  
43 (43%)  
47 (47%)  
12 (12%) 
47 (47%) 
92 (91%) 
45 (45%) 
21 (21%) 
8 (8%) 
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Haematological disease 
Positive anti-nuclear antibodies 
Positive dsDNA, Sm or APA antibodies   
73 (72%) 
96 (95%) 
80 (79%) 
Marital status (n=94) 
  
 
Married 
Single 
Divorced 
53 (56%) 
36 (38%) 
5 (5%) 
Table 2: Patient Baseline Disease activity, Damage and HRQoL, n (%) unless stated   
 
BILAG-2004: Index Mean (SD)  16.4 (8.1) 
Mean (SD) SLICC ACR-DI (n=98) 
SLICC ACR-DI:  
  
 
Score of 0  
Score of 1 
Score of 2 
Score of 3 or more   
0.56 (1.18) 
71 (72%)  
14 (14%)  
6 (6%)  
7 (7%) 
Mean (SD) LupusQoL Domain 
Scores  
 
Physical health 
Pain 
Planning 
Intimate relationships 
Burden to others 
Emotional health 
Body Image 
 Fatigue 
42.6 (26.6) 
40.9 (28.0) 
46.4 (32.2) 
37.8 (33.5) 
33.3 (28.2) 
51.4 (25.8) 
45.5 (29.1) 
34.1 (26.0) 
Mean (SD) SF-36 Domain 
Scores  
Physical Functioning 
Bodily Pain 
38.1 (26.9) 
31.8 (23.1) 
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Social Functioning 
General Health Perceptions 
Role Emotional 
Mental Health 
Role Physical 
Vitality 
42.3 (29.7) 
25.0 (18.6) 
28.7 (39.4) 
51.0 (21.5) 
12.1 (27.5) 
21.9 (20.0) 
Table 3: Mean (95%CI) change in score [number of contributing participants; number of 
valid change observations] of LupusQoL and SF-36 in comparable domains by Global Rating 
of Change category  
 
GRC category 
[101; 776] 
LupusQoL 
Pain 
SF-36 
Bodily Pain 
LupusQoL 
Physical Health 
SF-36 
Physical Functioning 
Deterioration 
(-7 to -2) 
-6.5 (-8.9 to -4.1) 
[72;195] 
-7.0 (-9.3 to -4.7) 
[86;254] 
-3.7 (-5.2 to -2.1) 
[72;188] 
-3.0 (-4.3 to -1.6) 
[75;209] 
Stable 
(-1 to +1) 
1.5 (0.2 to 2.7) 
[89;307] 
2.8 (1.1 to 4.5)  
[80;263] 
0.6 (-0.4 to 1.6) 
[90;298] 
1.2 (0.3 to 2.2)  
[89;293] 
Improvement 
(+2 to +7) 
9.3 (7.1 to 11.5) 
[80;258] 
13.0 (10.6 to 15.4) 
[74;231] 
5.6 (4.2 to 7.1) 
[83;282] 
5.6 (3.9 to 7.3) 
[77;249] 
GRC category 
[101;  776] 
LupusQoL 
Emotional Health 
SF-36 
Mental Health 
LupusQoL 
Fatigue 
SF-36 
Vitality 
Deterioration 
(-7 to -2) 
-4.4 (-6.0 to -2.7) 
[78;213] 
-5.5 (-7.5 to -3.6) 
[80;234] 
-4.6 (-6.5 to -2.8) 
[81;256] 
-4.6 (-6.3 to -2.8) 
[85;286] 
Stable 1.2 (0.1 to 2.3) -0.1 (-1.6 to 1.4)  2.1 (0.6 to 3.6) 0.9 (-0.8 to 2.6)  
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(-1 to +1) [92;304] [84;283] [88;296] [86;283] 
Improvement 
(+2 to +7) 
6.2 (4.7 to 7.8) 
[74;243] 
7.6 (5.9 to 9.4) 
[72;238] 
8.9 (6.8 to 11.0) 
[62;203] 
11.2 (8.4 to 14.0) 
[62;188] 
 
 
 
 
 
Table 4: Mean (95%CI) change in score [number of contributing participants; number of 
valid change observations] of LupusQoL and SF-36 in non-comparable domains by Global 
Rating of Change category  
 
GRC category 
[101;776] 
LupusQoL 
Body Image 
 
LupusQoL 
Planning 
 
LupusQoL 
Intimate 
Relationships 
LupusQoL 
Burden to others 
 
Deterioration 
(-7 to -2) 
-2.5 (-4.2 to -0.8) 
[67;197] 
-4.6 (-7.0 to -2.2) 
[64;164] 
-7.7 (-14.7 to -0.6) 
[42;75] 
-4.6 (-6.9 to -2.3) 
[70;195] 
Stable 
(-1 to +1) 
1.4 (0.3 to 2.5) 
[79;296] 
1.2 (0.0 to 2.4) 
[93;391] 
0.9 (-1.0 to 2.8) 
[74;338] 
2.5 (1.2 to 3.8) 
[94;397] 
Improvement 
(+2 to +7) 
6.4 (3.6 to 9.2) 
[47;122] 
6.3 (3.9 to 8.8) 
[65;206] 
8.3(4.3 to 12.4) 
[45;120] 
10.4 (7.7 to 13.1) 
[57;167] 
GRC category 
[101; 776] 
SF-36 
General Health 
 
SF-36 
Role Emotional 
 
SF-36 
Role Physical 
 
SF-36 
Social 
Functioning 
Deterioration -2.0 (-3.2 to -0.8) -10.1 (-15.9 to -4.3) -9.9 (-15.3 to -4.5) -7.0 (-10.8 to -
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(-7 to -2) [84;240] [69;182] [71;185] 3.1) [69;178] 
Stable 
(-1 to +1) 
0.3 (-0.6 to 1.2) 
[87;265] 
2.6 (-0.3 to 5.4) 
[89;363] 
1.4 (-1.3 to 4.0) 
[90;339] 
1.6 (0.1 to 3.2) 
[92;390] 
Improvement 
(+2 to +7) 
3.4  (2.2 to 4.6) 
[79;259] 
11.3 (6.6 to 15.9) 
[67;204] 
14.7 (9.9 to 19.5) 
[72;223] 
10.1 (7.0 to 13.2) 
[66;190] 
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Table 5: Minimal important change estimates for LupusQoL and SF-36 in comparable and 
non-comparable domains via anchor-based, MID(a), mean (95% Confidence Interval) by 
Global Rating of Change (GRC) category 
 
Comparable Domains Deterioration (GRC: -3 or -2) Improvement (GRC: +2 or +3) 
LupusQoL Pain -4.7 (-7.6 to -1.7) 6.8 (4.4 to 9.1) 
SF-36 Pain -6.7 (-9.4 to -4.0) 10.9 (8.0 to 13.8) 
LupusQoL Physical Health -3.4 (-5.1 to -1.8) 4.0 (2.2 to 5.8) 
SF-36 Physical Function -2.4 (-4.3 to -0.5) 3.8 (1.8 to 5.8)  
LupusQoL Emotional Health -3.7 (-5.7 to -1.7) 4.7 (2.6 to 6.7) 
SF-36 Mental Health -5.1 (-7.1 to -3.2) 7.5 (5.3 to 9.8) 
LupusQoL Fatigue -3.2 (-5.4 to -1.0)  6.6 (4.0 to 9.1)  
SF-36 Vitality -3.5 (-5.5 to -1.4) 10.9 (7.5 to 14.3) 
Non-comparable Domains   
LupusQoL Body Image -2.4 (-4.8 to 0.1) 3.5 (0.5 to 6.5) 
LupusQoL Planning -4.0 (-7.4 to -0.6) 3.8 (0.9 to 6.6) 
LupusQoL Intimate 
Relationship 
 
-8.7 (-18.9 to 1.6) 
 
7.1 (2.1 to 12.2) 
LupusQoL Burden to Others -5.0 (-7.8 to -2.1) 7.3 (4.0 to 10.6) 
SF-36 General Health -2.0 (-3.4 to -0.5) 2.8 (1.2 to 4.5) 
SF-36 Role Emotional -10.4 (-18.1 to -2.7) 10.2 (2.4 to 18.0) 
SF-36 Role Physical -11.1 (-17.8 to -4.5) 10.8 (4.3 to 17.4) 
SF-36 Social Functioning -4.2 (-8.8 to 0.3) 9.6 (5.4 to 13.8) 
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Figure 1: Flow diagram of patient progress through study procedures 
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